|Bid||11.80 x 63700|
|Ask||11.90 x 61200|
|Day's Range||11.50 - 11.50|
|52 Week Range||8.60 - 15.20|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||16.17|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shareholder rights law firm Robbins LLP announces that a purchaser of Corcept Therapeutics Incorporated (NASDAQ: CORT) filed a complaint against the company's officers and directors for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the Securities Exchange Act of 1934. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept's drug Korylm is a cortisol receptor blocker used to control hyperglycemia.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
The Menlo Park, California-based company said it had net income of 15 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The drug developer posted revenue of $64.8 million ...
Corcept Therapeutics Inc. (CORT) is one of them. Warning! GuruFocus has detected 3 Warning Signs with CORT. With Corcept set to earn upwards of $1 per share in 2019, it is probably fairly valued at its current cap.
An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.